Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells

Anti-Cancer Drugs

Volumn 24, Issue 5, 2013, Pages 519-526

  Fahey, Christine E ^a   Milner, Rowan J ^a   Kow, Kelvin ^a   Bacon, Nicholas J ^a   Salute, Marc E ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

canine osteosarcoma; comparative oncology; masitinib mesylate; tyrosine kinase inhibitor

Indexed keywords

CASPASE 3; CASPASE 7; MASITINIB; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG MECHANISM; ENZYME ACTIVITY; IC 50; IN VITRO STUDY; NICK END LABELING; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; SUPERNATANT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875836236     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32836002ba     Document Type: Article

References (45)

1. Brodey RS, Riser WH. Canine osteosarcoma. A clinicopathologic study of 194 cases. Clin Orthop Relat Res 1969; 62:54-64.
2. Brodey RS, McGrath JT, Reynolds H. A clinical and radiological study of canine bone neoplasms. I. J Am Vet Med Assoc 1959; 134:53-71.
3. Brodey RS, Sauer RM, Medway W. Canine bone neoplasms. J Am Vet Med Assoc 1963; 143:471-495.
4. Ling GV, Morgan JP, Pool RR. Primary bone rumors in the dog: a combined clinical, radiographic, and histologic approach to early diagnosis. J Am Vet Med Assoc 1974; 165:55-67.
5. Heyman SJ, Diefenderfer DL, Goldschmidt MH, Newton CD. Canine axial skeletal osteosarcoma. A retrospective study of 116 cases (1986 to 1989). Vet Surg 1992; 21:304-310.
6. Mauldin GN, Matus RE, Withrow SJ, Patnaik AK. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988; 2:177-180.
7. Spodnick GJ, Berg J, Rand WM, Schelling SH, Couto G, Harvey HJ, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992; 200:995-999.
8. Shapiro W, Fossum TW, Kitchell BE, Couto CG, Theilen GH. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988; 192:507-511. (Pubitemid 18044676)
9. Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs - 30 cases (1979-1990). J Am Vet Med Assoc 1992; 200:531-533.
10. Bacon NJ, Ehrhart NP, Dernell WS, Lafferty M, Withrow SJ. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). J Am Vet Med Assoc 2008; 232:1504-1510. (Pubitemid 351703453)
11. Straw RC, Withrow SJ, Richter SL, Powers BE, Klein MK, Postorino NC, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991; 5:205-210.
12. Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996; 10:76-81. (Pubitemid 126700927)
13. Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995; 206:1555-1560.
14. Chun R, Kurzman ID, Couto CG, Klausner J, Henry C, MacEwen EG. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study. J Vet Intern Med 2000; 14:495-498.
15. Kent MS, Strom A, London CA, Seguin B. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. J Vet Intern Med 2004; 18:540-544. (Pubitemid 39107546)
16. Bailey D, Erb H, Williams L, Ruslander D, Hauck M. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern Med 2003; 17:199-205. (Pubitemid 37465355)
17. Schiffer CA. Signal transduction inhibition: changing paradigms in cancer care. Semin Oncol 2001; 28:34-39. (Pubitemid 33140516)
18. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21:499-512. (Pubitemid 32959239)
19. Berns A, Mikkers H, Krimpenfort P, Allen J, Scheijen B, Jonkers J. Identification and characterization of collaborating oncogenes in compound mutant mice. Cancer Res 1999; 59:1773s-1777s. (Pubitemid 29165253)
20. Griffin J. The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol 2001; 28:3-8. (Pubitemid 33140512)
21. Kung HJ, Chen HC, Robinson D. Molecular profiling of tyrosine kinases in normal and cancer cells. J Biomed Sci 1998; 5:74-78. (Pubitemid 28253096)
22. Westermark B, Heldin CH. Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth. Acta Oncol 1993; 32:101-105. (Pubitemid 23188521)
23. Jakeman LB, Armanini M, Phillips HS, Ferrara N. Developmental expression of binding-sites and messenger-ribonucleic-acid for vascular endothelial growth-factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993; 133:848-859. (Pubitemid 23238902)
24. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 2000; 79:1-38.
25. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277:48-50. (Pubitemid 27450640)
26. Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, et al. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res 2010; 71:1354-1361.
27. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009; 4:e7258.
28. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson Jr. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011; 29:1039-1045.
29. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29:1046-1051.
30. Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, et al. Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study. Vet J 2012; 191:131-134.
31. Humbert M, Casteran N, Letard S, Hanssens K, Iovanna J, Finetti P, et al. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS One 2010; 5:e9430.
32. Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, et al. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2010; 66:395-403.
33. Levine RA. Overexpression of the sis oncogene in a canine osteosarcoma cell line. Vet Pathol 2002; 39:411-412.
34. Wolfesberger B, Tonar Z, Gerner W, Skalicky M, Heiduschka G, Egerbacher M, et al. The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. Res Vet Sci 2010; 88:94-100.
35. Wergin MC, Kaser-Hotz B. Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours. In Vivo 2004; 18:15-19.
36. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Bloodbased biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13:2643-2650. (Pubitemid 46788031)
37. Motzer RJ, Michaelson MD, Redman BG, Hudes GR,Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24. (Pubitemid 46630489)
38. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 2010; 16:4853-4863.
39. Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 2009; 15:263-268.
40. Barroga EF, Kadosawa T, Okumura M, Fujinaga T. Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. J Vet Med Sci 1999; 61:361-367. (Pubitemid 129620054)
41. Shoieb AM, Hahn KA, Barnhill MA. An in vivo in vitro experimental model system for the study of human osteosarcoma: canine osteosarcoma cells (COS31) which retain osteoblastic and metastatic properties in nude mice. In Vivo 1998; 12:463-472. (Pubitemid 28517689)
42. Hahn KA, Oglivie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008; 22:1301-1309.
43. Lyles SE, Milner RJ, Kow K, Salute ME. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. Vet Comp Oncol 2012; 10:223-235.
44. Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 2011; 11:125.
45. Thamm DH, O'Brien MG, Vail DM. Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. Vet Comp Oncol 2008; 6:126-132.